2011-02-01
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users
Publication
Publication
Neurogenetics , Volume 12 - Issue 1 p. 79- 82
Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p∈=∈0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p∈=∈0.045).
| Additional Metadata | |
|---|---|
| , , , , , , , , , , , , , , , , , , , , | |
| doi.org/10.1007/s10048-010-0254-5, hdl.handle.net/1765/23520 | |
| Neurogenetics | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Becker, M., Visser, L., van Schaik, R., Hofman, A., Uitterlinden, A., & Stricker, B. (2011). OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics, 12(1), 79–82. doi:10.1007/s10048-010-0254-5 |
|
